Skip to main content
Premium Trial:

Request an Annual Quote

Informax Licenses Genomax to Cellular Genomics

NEW YORK, May 14 – Bioinformatics company Informax said Monday it signed a deal in the first quarter to license its Genomax software to Cellular Genomics.

An Informax spokeswoman said the deal was recorded in the company’s first quarter earnings although the official announcement was held up due to internal delays.

“These products will form a key element of CGI's bioinformatics infrastructure, allowing us to rapidly meet our needs of high throughput sequence analysis for our protein-protein interaction screens, as well as gene expression analysis for our target validation work,” Andy Whitney, Cellular Genomics’ director of bioinformatics, said in a statement.

Terms of the deal were not disclosed.

Genomax is an enterprise system that supports high-throughput research. Genomax can handle genomic and proteomic data, including sequence information, gene expression data, and protein structure.

To date, Informax of Bethesda, Md., has licensed Genomax to over 30 pharmaceutical, biotechnology, and academic customers.

Cellular Genomics of Branford, Conn., identifies and validates novel drug targets and plans to develop its own pharmaceutical products.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.